Sertraline to treat hot flashes: A randomized controlled, double-blind, crossover trial in a general population

Paul R Gordon, James P. Kerwin, Kelly Green Boesen, Janet Senf

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the effectiveness of a selective serotonin reuptake inhibitor (SSRI) (sertraline) in decreasing hot flashes in a general population of women. DESIGN: A double-blind, placebo-controlled, crossover trial was conducted in a southwestern urban setting. A total of 102 women aged 40 to 65 who were experiencing hot flashes and not taking any hormone therapy were recruited. After 1 week of baseline hot flash data collection, study participants were randomized to receive placebo or active drug (sertraline 50 mg) for 4 weeks. This intervention was followed by a 1-week washout and cross over to the opposite treatment for 4 weeks. The number and severity of hot flashes were measured. RESULTS: One hundred two women were enrolled in the study. Five dropped out before providing baseline data. Of the 97 remaining, 52 were randomized to active drug first and 45 to placebo first. Ten dropped out of the study before completing all 10 weeks, leaving 46 in the active drug-first arm and 41 in the placebo-first arm. At baseline, the mean number of hot flashes reported was 45.6 per week (SD = 29.6), ranging from 2 to 148. During the sertraline phase of the study, women experienced five fewer hot flashes per week than they did on the placebo (P = 0.002). The severity of hot flashes was not significantly different; however, the hot flash score (number × average severity) was significantly improved during the sertraline phase. CONCLUSION: Sertraline reduced the number of hot flashes and improved the hot flash score relative to placebo and may be an acceptable alternative treatment for women experiencing hot flashes.

Original languageEnglish (US)
Pages (from-to)568-575
Number of pages8
JournalMenopause
Volume13
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

Hot Flashes
Sertraline
Cross-Over Studies
Population
Placebos
Pharmaceutical Preparations
Serotonin Uptake Inhibitors
Therapeutics

Keywords

  • Hot flashes
  • Menopause
  • Selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Sertraline to treat hot flashes : A randomized controlled, double-blind, crossover trial in a general population. / Gordon, Paul R; Kerwin, James P.; Boesen, Kelly Green; Senf, Janet.

In: Menopause, Vol. 13, No. 4, 07.2006, p. 568-575.

Research output: Contribution to journalArticle

Gordon, Paul R ; Kerwin, James P. ; Boesen, Kelly Green ; Senf, Janet. / Sertraline to treat hot flashes : A randomized controlled, double-blind, crossover trial in a general population. In: Menopause. 2006 ; Vol. 13, No. 4. pp. 568-575.
@article{a1678922b21e41f3a63f38738bd82ab8,
title = "Sertraline to treat hot flashes: A randomized controlled, double-blind, crossover trial in a general population",
abstract = "OBJECTIVE: To evaluate the effectiveness of a selective serotonin reuptake inhibitor (SSRI) (sertraline) in decreasing hot flashes in a general population of women. DESIGN: A double-blind, placebo-controlled, crossover trial was conducted in a southwestern urban setting. A total of 102 women aged 40 to 65 who were experiencing hot flashes and not taking any hormone therapy were recruited. After 1 week of baseline hot flash data collection, study participants were randomized to receive placebo or active drug (sertraline 50 mg) for 4 weeks. This intervention was followed by a 1-week washout and cross over to the opposite treatment for 4 weeks. The number and severity of hot flashes were measured. RESULTS: One hundred two women were enrolled in the study. Five dropped out before providing baseline data. Of the 97 remaining, 52 were randomized to active drug first and 45 to placebo first. Ten dropped out of the study before completing all 10 weeks, leaving 46 in the active drug-first arm and 41 in the placebo-first arm. At baseline, the mean number of hot flashes reported was 45.6 per week (SD = 29.6), ranging from 2 to 148. During the sertraline phase of the study, women experienced five fewer hot flashes per week than they did on the placebo (P = 0.002). The severity of hot flashes was not significantly different; however, the hot flash score (number × average severity) was significantly improved during the sertraline phase. CONCLUSION: Sertraline reduced the number of hot flashes and improved the hot flash score relative to placebo and may be an acceptable alternative treatment for women experiencing hot flashes.",
keywords = "Hot flashes, Menopause, Selective serotonin reuptake inhibitor",
author = "Gordon, {Paul R} and Kerwin, {James P.} and Boesen, {Kelly Green} and Janet Senf",
year = "2006",
month = "7",
doi = "10.1097/01.gme.0000196595.82452.ca",
language = "English (US)",
volume = "13",
pages = "568--575",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Sertraline to treat hot flashes

T2 - A randomized controlled, double-blind, crossover trial in a general population

AU - Gordon, Paul R

AU - Kerwin, James P.

AU - Boesen, Kelly Green

AU - Senf, Janet

PY - 2006/7

Y1 - 2006/7

N2 - OBJECTIVE: To evaluate the effectiveness of a selective serotonin reuptake inhibitor (SSRI) (sertraline) in decreasing hot flashes in a general population of women. DESIGN: A double-blind, placebo-controlled, crossover trial was conducted in a southwestern urban setting. A total of 102 women aged 40 to 65 who were experiencing hot flashes and not taking any hormone therapy were recruited. After 1 week of baseline hot flash data collection, study participants were randomized to receive placebo or active drug (sertraline 50 mg) for 4 weeks. This intervention was followed by a 1-week washout and cross over to the opposite treatment for 4 weeks. The number and severity of hot flashes were measured. RESULTS: One hundred two women were enrolled in the study. Five dropped out before providing baseline data. Of the 97 remaining, 52 were randomized to active drug first and 45 to placebo first. Ten dropped out of the study before completing all 10 weeks, leaving 46 in the active drug-first arm and 41 in the placebo-first arm. At baseline, the mean number of hot flashes reported was 45.6 per week (SD = 29.6), ranging from 2 to 148. During the sertraline phase of the study, women experienced five fewer hot flashes per week than they did on the placebo (P = 0.002). The severity of hot flashes was not significantly different; however, the hot flash score (number × average severity) was significantly improved during the sertraline phase. CONCLUSION: Sertraline reduced the number of hot flashes and improved the hot flash score relative to placebo and may be an acceptable alternative treatment for women experiencing hot flashes.

AB - OBJECTIVE: To evaluate the effectiveness of a selective serotonin reuptake inhibitor (SSRI) (sertraline) in decreasing hot flashes in a general population of women. DESIGN: A double-blind, placebo-controlled, crossover trial was conducted in a southwestern urban setting. A total of 102 women aged 40 to 65 who were experiencing hot flashes and not taking any hormone therapy were recruited. After 1 week of baseline hot flash data collection, study participants were randomized to receive placebo or active drug (sertraline 50 mg) for 4 weeks. This intervention was followed by a 1-week washout and cross over to the opposite treatment for 4 weeks. The number and severity of hot flashes were measured. RESULTS: One hundred two women were enrolled in the study. Five dropped out before providing baseline data. Of the 97 remaining, 52 were randomized to active drug first and 45 to placebo first. Ten dropped out of the study before completing all 10 weeks, leaving 46 in the active drug-first arm and 41 in the placebo-first arm. At baseline, the mean number of hot flashes reported was 45.6 per week (SD = 29.6), ranging from 2 to 148. During the sertraline phase of the study, women experienced five fewer hot flashes per week than they did on the placebo (P = 0.002). The severity of hot flashes was not significantly different; however, the hot flash score (number × average severity) was significantly improved during the sertraline phase. CONCLUSION: Sertraline reduced the number of hot flashes and improved the hot flash score relative to placebo and may be an acceptable alternative treatment for women experiencing hot flashes.

KW - Hot flashes

KW - Menopause

KW - Selective serotonin reuptake inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33746102870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746102870&partnerID=8YFLogxK

U2 - 10.1097/01.gme.0000196595.82452.ca

DO - 10.1097/01.gme.0000196595.82452.ca

M3 - Article

C2 - 16837878

AN - SCOPUS:33746102870

VL - 13

SP - 568

EP - 575

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 4

ER -